Pfizer's acquisition of El build, investors are not optimistic about?

Al built on Zhou Huirui finally reached a merger agreement is expected to become the world's largest pharmaceutical companies. It is reported that the proposed merger will be subject to the approval of both the United States and European regulators will ultimately complete the merger in 2016. Supposedly giant's share price will likely skyrocket to win the favor of investors.
However, recent global financial news CNBC host Jim Cramer, but that the situation is not as clear as expected. In addition to Jim Cramer, Nomura Securities analyst Shibani Malhotra also said that despite the merger agreement reached after, Al-built stock prices rebounded, but investors are still difficult to recognize the long-term potential value of this transaction brings.
Al build than the current stock price of $ 370.53 15.9% expected lower share value that the company reached a merger agreement substantially undervalued by investors.
So how the actual situation? What are the main points to be ignored investors?
First, the new company's headquarters will be based in Ireland, which is also the maximum income tax inversion. This will bring to El build a more flexible fiscal, while resulting in increased dividends, and this is currently ignored by investors. Al dividend currently built not more than 52 US dollars, while it is estimated that Pfizer's dividend will reach $ 52.53.
Followed by Pfizer expanding global map. Pfizer's global market is expanding, while Al Jian said that after the merger will help Pfizer to penetrate into China and Japan and other major markets. Built for Al, the ophthalmic pharmaceutical market in Asia and gastrointestinal disease drug market in Europe will be a very important opportunity.
In addition, Al build current executives - such as CEO Brent Saunders will serve as the new company COO, and current chairman Paul Bisaro will also held senior positions in the new company. This will effectively strengthen the new company's management and promotion.
Al build long continue to uphold the "growth-oriented pharmaceutical" model and philosophy, coupled with the combined use of Pfizer larger platform, its development will be more flourishing.